NewAmsterdam Pharma N.V.

Contributing Author

Recent Articles by NewAmsterdam Pharma N.V.

Nov-07	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS GlobeNewswire
Nov-05	NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results NAMS GlobeNewswire
Oct-30	NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November NAMS GlobeNewswire
Sep-24	NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum NAMS GlobeNewswire
Aug-25	NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September NAMS GlobeNewswire
Aug-18	NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib NAMS GlobeNewswire
Aug-06	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results NAMS GlobeNewswire
Jul-30	NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025 NAMS GlobeNewswire
Jul-22	NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025 NAMS GlobeNewswire
Jun-09	NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial NAMS GlobeNewswire
Jun-05	NewAmsterdam Pharma to Host R&D Day on June 11, 2025 NAMS GlobeNewswire
May-27	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June NAMS GlobeNewswire
May-14	NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference NAMS GlobeNewswire
May-08	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results NAMS GlobeNewswire
May-07	NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025 NAMS GlobeNewswire
May-02	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.